Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperforin is a phloroglucinol derivative and the primary active constituent responsible for the antidepressant and anxiolytic properties of St. John's wort (Hypericum perforatum) extracts. It acts as a broad-spectrum reuptake inhibitor of monoamines, including serotonin, norepinephrine, dopamine, as well as GABA and glutamate. Unlike conventional antidepressants that target specific transporters, hyperforin inhibits neurotransmitter uptake by activating the transient receptor potential ion channel TRPC6, leading to increased intracellular sodium and calcium concentrations which in turn inhibit monoamine reuptake. Hyperforin also induces cytochrome P450 enzymes CYP3A4 and CYP2C9 via activation of the pregnane X receptor (PXR), contributing to significant drug interactions when St. John's wort is used concurrently with other medications. In addition to its antidepressant effects, hyperforin exhibits anxiolytic-like activity, cognition-enhancing effects in vivo, antioxidant properties in vitro, anticyclooxygenase-1 activity, and potential anticarcinogenic effects[1][2][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperforin.